Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 2
2007 2
2009 2
2012 2
2013 1
2014 1
2015 1
2016 4
2017 3
2018 2
2019 2
2020 6
2021 6
2022 5
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Immune checkpoint therapy-current perspectives and future directions.
Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, Herbrich SM, Anandhan S, Islam S, Amit M, Anandappa G, Allison JP. Sharma P, et al. Among authors: goswami s. Cell. 2023 Apr 13;186(8):1652-1669. doi: 10.1016/j.cell.2023.03.006. Cell. 2023. PMID: 37059068 Free article. Review.
Myeloid cell-targeted therapies for solid tumours.
Goswami S, Anandhan S, Raychaudhuri D, Sharma P. Goswami S, et al. Nat Rev Immunol. 2023 Feb;23(2):106-120. doi: 10.1038/s41577-022-00737-w. Epub 2022 Jun 13. Nat Rev Immunol. 2023. PMID: 35697799 Review.
The Next Decade of Immune Checkpoint Therapy.
Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JP. Sharma P, et al. Among authors: goswami s. Cancer Discov. 2021 Apr;11(4):838-857. doi: 10.1158/2159-8290.CD-20-1680. Cancer Discov. 2021. PMID: 33811120 Review.
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma.
Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, Vence L, Blando J, Zhao H, Yadav SS, Ott M, Kong LY, Heimberger AB, de Groot J, Sepesi B, Overman M, Kopetz S, Allison JP, Pe'er D, Sharma P. Goswami S, et al. Nat Med. 2020 Jan;26(1):39-46. doi: 10.1038/s41591-019-0694-x. Epub 2019 Dec 23. Nat Med. 2020. PMID: 31873309 Free PMC article.
Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade.
Goswami S, Raychaudhuri D, Singh P, Natarajan SM, Chen Y, Poon C, Hennessey M, Tannir AJ, Zhang J, Anandhan S, Kerrigan BP, Macaluso MD, He Z, Jindal S, Lang FF, Basu S, Sharma P. Goswami S, et al. Nat Cancer. 2023 Oct;4(10):1455-1473. doi: 10.1038/s43018-023-00620-0. Epub 2023 Aug 31. Nat Cancer. 2023. PMID: 37653141
Frontiers in cancer immunotherapy-a symposium report.
Cable J, Greenbaum B, Pe'er D, Bollard CM, Bruni S, Griffin ME, Allison JP, Wu CJ, Subudhi SK, Mardis ER, Brentjens R, Sosman JA, Cemerski S, Zavitsanou AM, Proia T, Egeblad M, Nolan G, Goswami S, Spranger S, Mackall CL. Cable J, et al. Among authors: goswami s. Ann N Y Acad Sci. 2021 Apr;1489(1):30-47. doi: 10.1111/nyas.14526. Epub 2020 Nov 13. Ann N Y Acad Sci. 2021. PMID: 33184911 Review.
Immune Checkpoint Therapies in Prostate Cancer.
Goswami S, Aparicio A, Subudhi SK. Goswami S, et al. Cancer J. 2016 Mar-Apr;22(2):117-20. doi: 10.1097/PPO.0000000000000176. Cancer J. 2016. PMID: 27111907 Free PMC article. Review.
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.
Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, Basu S, Duan F, Jindal S, Zhang Y, Chen H, Yadav SS, Shazer R, Der-Torossian H, Allison JP, Sharma P, Tannir NM. Msaouel P, et al. Among authors: goswami s. Sci Transl Med. 2022 Apr 20;14(641):eabm6420. doi: 10.1126/scitranslmed.abm6420. Epub 2022 Apr 20. Sci Transl Med. 2022. PMID: 35442707 Clinical Trial.
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.
Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Gao J, et al. Among authors: goswami s. Nat Med. 2020 Dec;26(12):1845-1851. doi: 10.1038/s41591-020-1086-y. Epub 2020 Oct 12. Nat Med. 2020. PMID: 33046869 Free PMC article. Clinical Trial.
Investigative needle core biopsies for multi-omics in Glioblastoma.
Yu KKH, Basu S, Baquer G, Ahn R, Gantchev J, Jindal S, Regan MS, Abou-Mrad Z, Prabhu MC, Williams MJ, D'Souza AD, Malinowski SW, Hopland K, Elhanati Y, Stopka SA, Stortchevoi A, He Z, Sun J, Chen Y, Espejo AB, Chow KH, Yerrum S, Kao PL, Kerrigan BP, Norberg L, Nielsen D; GBM TeamLab; Puduvalli VK, Huse J, Beroukhim R, Kim YSB, Goswami S, Boire A, Frisken S, Cima MJ, Holdhoff M, Lucas CG, Bettegowda C, Levine SS, Bale TA, Brennan C, Reardon DA, Lang FF, Antonio Chiocca E, Ligon KL, White FM, Sharma P, Tabar V, Agar NYR. Yu KKH, et al. Among authors: goswami s. medRxiv [Preprint]. 2023 Dec 31:2023.12.29.23300541. doi: 10.1101/2023.12.29.23300541. medRxiv. 2023. PMID: 38234840 Free PMC article. Preprint.
41 results